Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 278

1.

Discovering translational biomarkers in neurodevelopmental disorders.

Sahin M, Jones SR, Sweeney JA, Berry-Kravis E, Connors BW, Ewen JB, Hartman AL, Levin AR, Potter WZ, Mamounas LA.

Nat Rev Drug Discov. 2018 Dec 20. doi: 10.1038/d41573-018-00010-7. [Epub ahead of print] No abstract available.

PMID:
30936503
2.

A multicenter study of ketamine effects on functional connectivity: Large scale network relationships, hubs and symptom mechanisms.

Fleming LM, Javitt DC, Carter CS, Kantrowitz JT, Girgis RR, Kegeles LS, Ragland JD, Maddock RJ, Lesh TA, Tanase C, Robinson J, Potter WZ, Carlson M, Wall MM, Choo TH, Grinband J, Lieberman J, Krystal JH, Corlett PR.

Neuroimage Clin. 2019;22:101739. doi: 10.1016/j.nicl.2019.101739. Epub 2019 Feb 28.

3.

Novel prodrug PRX-P4-003, selectively activated by gut enzymes, may reduce the risk of iatrogenic addiction and abuse.

Patil ST, Bihovsky RH, Smith SA, Potter WZ, Stella VJ.

Drug Alcohol Depend. 2018 May 1;186:159-166. doi: 10.1016/j.drugalcdep.2017.12.042. Epub 2018 Mar 2.

PMID:
29574296
4.

Utility of Imaging-Based Biomarkers for Glutamate-Targeted Drug Development in Psychotic Disorders: A Randomized Clinical Trial.

Javitt DC, Carter CS, Krystal JH, Kantrowitz JT, Girgis RR, Kegeles LS, Ragland JD, Maddock RJ, Lesh TA, Tanase C, Corlett PR, Rothman DL, Mason G, Qiu M, Robinson J, Potter WZ, Carlson M, Wall MM, Choo TH, Grinband J, Lieberman JA.

JAMA Psychiatry. 2018 Jan 1;75(1):11-19. doi: 10.1001/jamapsychiatry.2017.3572.

5.

The crisis in recruitment for clinical trials in Alzheimer's and dementia: An action plan for solutions.

Fargo KN, Carrillo MC, Weiner MW, Potter WZ, Khachaturian Z.

Alzheimers Dement. 2016 Nov;12(11):1113-1115. doi: 10.1016/j.jalz.2016.10.001. No abstract available.

PMID:
27836052
6.

Derisking Psychiatric Drug Development: The NIMH's Fast Fail Program, A Novel Precompetitive Model.

Grabb MC, Cross AJ, Potter WZ, McCracken JT.

J Clin Psychopharmacol. 2016 Oct;36(5):419-21. doi: 10.1097/JCP.0000000000000536. No abstract available.

7.

Revolutionizing Alzheimer's disease and clinical trials through biomarkers.

Mattsson N, Carrillo MC, Dean RA, Devous MD Sr, Nikolcheva T, Pesini P, Salter H, Potter WZ, Sperling RS, Bateman RJ, Bain LJ, Liu E.

Alzheimers Dement (Amst). 2015 Oct 3;1(4):412-9. doi: 10.1016/j.dadm.2015.09.001. eCollection 2015 Dec. Review.

8.

Biomarkers of Brain Structure and Function for Neurodegenerative Disorders: Are They Adequate for Go/No Go Decisions in Drug Development?

Potter WZ.

Clin Pharmacol Ther. 2015 Nov;98(5):472-4. doi: 10.1002/cpt.196. Epub 2015 Sep 29. Review.

PMID:
26418882
9.

High Resolution Discovery Proteomics Reveals Candidate Disease Progression Markers of Alzheimer's Disease in Human Cerebrospinal Fluid.

Hendrickson RC, Lee AY, Song Q, Liaw A, Wiener M, Paweletz CP, Seeburger JL, Li J, Meng F, Deyanova EG, Mazur MT, Settlage RE, Zhao X, Southwick K, Du Y, Holder D, Sachs JR, Laterza OF, Dallob A, Chappell DL, Snyder K, Modur V, King E, Joachim C, Bondarenko AY, Shearman M, Soper KA, Smith AD, Potter WZ, Koblan KS, Sachs AB, Yates NA.

PLoS One. 2015 Aug 13;10(8):e0135365. doi: 10.1371/journal.pone.0135365. eCollection 2015.

10.

Perspective: The Alzheimer's Disease Neuroimaging Initiative and the role and contributions of the Private Partner Scientific Board (PPSB).

Liu E, Luthman J, Cedarbaum JM, Schmidt ME, Cole PE, Hendrix J, Carrillo MC, Jones-Davis D, Tarver E, Novak G, De Santi S, Soares HD, Potter WZ, Siemers E, Schwarz AJ.

Alzheimers Dement. 2015 Jul;11(7):840-9. doi: 10.1016/j.jalz.2015.04.001. Review.

PMID:
26194317
11.

Translational and Early Phase Strategies for Treatment Development: Report of ISCTM Autumn 2013 Symposium.

Young JW, Potter WZ, Riley S, Groeneveld GJ, Kinon BJ, Egan MF, Feltner DE.

Innov Clin Neurosci. 2015 Mar-Apr;12(3-4):5S-10S.

12.

Soluble BACE-1 Activity and sAβPPβ Concentrations in Alzheimer's Disease and Age-Matched Healthy Control Cerebrospinal Fluid from the Alzheimer's Disease Neuroimaging Initiative-1 Baseline Cohort.

Savage MJ, Holder DJ, Wu G, Kaplow J, Siuciak JA, Potter WZ; Foundation for National Institutes of Health (FNIH) Biomarkers Consortium CSF Proteomics Project Team for Alzheimer's Disease Neuroimaging Initiative.

J Alzheimers Dis. 2015;46(2):431-40. doi: 10.3233/JAD-142778.

13.

Development and evaluation of a multiplexed mass spectrometry based assay for measuring candidate peptide biomarkers in Alzheimer's Disease Neuroimaging Initiative (ADNI) CSF.

Spellman DS, Wildsmith KR, Honigberg LA, Tuefferd M, Baker D, Raghavan N, Nairn AC, Croteau P, Schirm M, Allard R, Lamontagne J, Chelsky D, Hoffmann S, Potter WZ; Alzheimer's Disease Neuroimaging Initiative; Foundation for NIH (FNIH) Biomarkers Consortium CSF Proteomics Project Team.

Proteomics Clin Appl. 2015 Aug;9(7-8):715-31. doi: 10.1002/prca.201400178. Epub 2015 Apr 24.

14.

Optimizing early Go/No Go decisions in CNS drug development.

Potter WZ.

Expert Rev Clin Pharmacol. 2015 Mar;8(2):155-7. doi: 10.1586/17512433.2015.991715. Epub 2014 Dec 24.

15.

Imaging as a biomarker in drug discovery for Alzheimer's disease: is MRI a suitable technology?

Merlo Pich E, Jeromin A, Frisoni GB, Hill D, Lockhart A, Schmidt ME, Turner MR, Mondello S, Potter WZ.

Alzheimers Res Ther. 2014 Jul 30;6(4):51. doi: 10.1186/alzrt276. eCollection 2014. Review.

16.

Cerebrospinal fluid biomarkers distinguish postmortem-confirmed Alzheimer's disease from other dementias and healthy controls in the OPTIMA cohort.

Seeburger JL, Holder DJ, Combrinck M, Joachim C, Laterza O, Tanen M, Dallob A, Chappell D, Snyder K, Flynn M, Simon A, Modur V, Potter WZ, Wilcock G, Savage MJ, Smith AD.

J Alzheimers Dis. 2015;44(2):525-39. doi: 10.3233/JAD-141725.

PMID:
25391385
17.

Current drug development for antidepressants and ideas addressing downstream glutamate: the ketamine example.

Potter WZ, Brady LS.

CNS Spectr. 2014 Apr;19(2):112-4. doi: 10.1017/S1092852914000029. Epub 2014 Feb 25. No abstract available.

PMID:
24565466
18.

Proteomic biomarkers for brain disorders: technical considerations and challenges.

Brady LS, Potter WZ.

Neuropsychopharmacology. 2014 Jan;39(1):252. doi: 10.1038/npp.2013.202. No abstract available.

19.

Public-private partnerships to revitalize psychiatric drug discovery.

Brady LS, Potter WZ.

Expert Opin Drug Discov. 2014 Jan;9(1):1-8. doi: 10.1517/17460441.2014.867944. Epub 2013 Dec 6.

PMID:
24308355
20.

Mining the secrets of the CSF: developing biomarkers of neurodegeneration.

Potter WZ.

J Clin Invest. 2012 Sep;122(9):3051-3. doi: 10.1172/JCI65309. Epub 2012 Aug 27.

21.

Plasma biomarkers associated with the apolipoprotein E genotype and Alzheimer disease.

Soares HD, Potter WZ, Pickering E, Kuhn M, Immermann FW, Shera DM, Ferm M, Dean RA, Simon AJ, Swenson F, Siuciak JA, Kaplow J, Thambisetty M, Zagouras P, Koroshetz WJ, Wan HI, Trojanowski JQ, Shaw LM; Biomarkers Consortium Alzheimer's Disease Plasma Proteomics Project.

Arch Neurol. 2012 Oct;69(10):1310-7.

22.

A Randomized, placebo-controlled, crossover pilot trial of the oral selective NR2B antagonist MK-0657 in patients with treatment-resistant major depressive disorder.

Ibrahim L, Diaz Granados N, Jolkovsky L, Brutsche N, Luckenbaugh DA, Herring WJ, Potter WZ, Zarate CA Jr.

J Clin Psychopharmacol. 2012 Aug;32(4):551-7. doi: 10.1097/JCP.0b013e31825d70d6.

23.

Decision-making using fMRI in clinical drug development: revisiting NK-1 receptor antagonists for pain.

Borsook D, Upadhyay J, Klimas M, Schwarz AJ, Coimbra A, Baumgartner R, George E, Potter WZ, Large T, Bleakman D, Evelhoch J, Iyengar S, Becerra L, Hargreaves RJ.

Drug Discov Today. 2012 Sep;17(17-18):964-73. doi: 10.1016/j.drudis.2012.05.004. Epub 2012 May 10. Review.

PMID:
22579743
24.

New Clinical Drug Evaluation Unit (NCDEU) annual meeting: a great opportunity for early career psychiatrists.

Kane JM, Hill LD, Kinon BJ, Potter WZ, Rapaport MH, Schooler NR.

J Clin Psychiatry. 2012 Apr;73(4):504-5. doi: 10.4088/JCP.12com07750. No abstract available.

PMID:
22579149
25.

New era for novel CNS drug development.

Potter WZ.

Neuropsychopharmacology. 2012 Jan;37(1):278-80. doi: 10.1038/npp.2011.186. No abstract available.

26.

Translating glutamate: from pathophysiology to treatment.

Javitt DC, Schoepp D, Kalivas PW, Volkow ND, Zarate C, Merchant K, Bear MF, Umbricht D, Hajos M, Potter WZ, Lee CM.

Sci Transl Med. 2011 Sep 28;3(102):102mr2. doi: 10.1126/scitranslmed.3002804. Review.

27.

Report of the task force on designing clinical trials in early (predementia) AD.

Aisen PS, Andrieu S, Sampaio C, Carrillo M, Khachaturian ZS, Dubois B, Feldman HH, Petersen RC, Siemers E, Doody RS, Hendrix SB, Grundman M, Schneider LS, Schindler RJ, Salmon E, Potter WZ, Thomas RG, Salmon D, Donohue M, Bednar MM, Touchon J, Vellas B.

Neurology. 2011 Jan 18;76(3):280-6. doi: 10.1212/WNL.0b013e318207b1b9. Epub 2010 Dec 22.

28.

The Alzheimer's disease neuroimaging initiative: perspectives of the Industry Scientific Advisory Board.

Schmidt ME, Siemers E, Snyder PJ, Potter WZ, Cole P, Soares H.

Alzheimers Dement. 2010 May;6(3):286-90. doi: 10.1016/j.jalz.2010.03.010.

PMID:
20451878
29.

Update on the biomarker core of the Alzheimer's Disease Neuroimaging Initiative subjects.

Trojanowski JQ, Vandeerstichele H, Korecka M, Clark CM, Aisen PS, Petersen RC, Blennow K, Soares H, Simon A, Lewczuk P, Dean R, Siemers E, Potter WZ, Weiner MW, Jack CR Jr, Jagust W, Toga AW, Lee VM, Shaw LM; Alzheimer's Disease Neuroimaging Initiative.

Alzheimers Dement. 2010 May;6(3):230-8. doi: 10.1016/j.jalz.2010.03.008. Review.

30.

Dose ranging for trials through biomarkers of drug effects.

Potter WZ.

J Nutr Health Aging. 2010 Apr;14(4):310-1.

PMID:
20306003
31.

ApoE genotyping as a progression-rate biomarker in phase II disease-modification trials for Alzheimer's disease.

Stone DJ, Molony C, Suver C, Schadt EE, Potter WZ.

Pharmacogenomics J. 2010 Jun;10(3):161-4. doi: 10.1038/tpj.2009.58. Epub 2009 Dec 8. No abstract available.

PMID:
19997085
32.

Benefits exceed risks of newer antidepressant medications in youth--maybe not.

Potter WZ.

Clin Pharmacol Ther. 2009 Oct;86(4):357-9. doi: 10.1038/clpt.2009.173. No abstract available.

PMID:
19763114
33.

A roadmap for the prevention of dementia II: Leon Thal Symposium 2008.

Khachaturian ZS, Snyder PJ, Doody R, Aisen P, Comer M, Dwyer J, Frank RA, Holzapfel A, Khachaturian AS, Korczyn AD, Roses A, Simpkins JW, Schneider LS, Albert MS, Egge R, Deves A, Ferris S, Greenberg BD, Johnson C, Kukull WA, Poirier J, Schenk D, Thies W, Gauthier S, Gilman S, Bernick C, Cummings JL, Fillit H, Grundman M, Kaye J, Mucke L, Reisberg B, Sano M, Pickeral O, Petersen RC, Mohs RC, Carrillo M, Corey-Bloom JP, Foster NL, Jacobsen S, Lee V, Potter WZ, Sabbagh MN, Salmon D, Trojanowski JQ, Wexler N, Bain LJ.

Alzheimers Dement. 2009 Mar;5(2):85-92. doi: 10.1016/j.jalz.2009.01.021.

34.

The history and current state of antidepressant clinical trial design: a call to action for proof-of-concept studies.

Gelenberg AJ, Thase ME, Meyer RE, Goodwin FK, Katz MM, Kraemer HC, Potter WZ, Shelton RC, Fava M, Khan A, Trivedi MH, Ninan PT, Mann JJ, Bergeson S, Endicott J, Kocsis JH, Leon AC, Manji HK, Rosenbaum JF.

J Clin Psychiatry. 2008 Oct;69(10):1513-28. Epub 2008 Oct 7. Erratum in: J Clin Psychiatry. 2008 Dec;69(12):1985.

PMID:
19192434
35.

Changes in brain function during administration of venlafaxine or placebo to normal subjects.

Leuchter AF, Cook IA, DeBrota DJ, Hunter AM, Potter WZ, McGrouther CC, Morgan ML, Abrams M, Siegman B.

Clin EEG Neurosci. 2008 Oct;39(4):175-81.

PMID:
19044214
36.

Selective muscarinic receptor agonist xanomeline as a novel treatment approach for schizophrenia.

Shekhar A, Potter WZ, Lightfoot J, Lienemann J, Dubé S, Mallinckrodt C, Bymaster FP, McKinzie DL, Felder CC.

Am J Psychiatry. 2008 Aug;165(8):1033-9. doi: 10.1176/appi.ajp.2008.06091591. Epub 2008 Jul 1.

PMID:
18593778
37.

Rofecoxib in patients with mild cognitive impairment: further analyses of data from a randomized, double-blind, trial.

Aisen PS, Thal LJ, Ferris SH, Assaid C, Nessly ML, Giuliani MJ, Lines CR, Norman BA, Potter WZ.

Curr Alzheimer Res. 2008 Feb;5(1):73-82.

PMID:
18288935
38.

Is bigger better for depression trials?

Liu KS, Snavely DB, Ball WA, Lines CR, Reines SA, Potter WZ.

J Psychiatr Res. 2008 Jul;42(8):622-30. Epub 2007 Sep 7.

PMID:
17825841
39.

Identifying pharmacodynamic protein markers of centrally active drugs in humans: a pilot study in a novel clinical model.

Patil ST, Higgs RE, Brandt JE, Knierman MD, Gelfanova V, Butler JP, Downing AM, Dorocke J, Dean RA, Potter WZ, Michelson D, Pan AX, Jhee SS, Hale JE.

J Proteome Res. 2007 Mar;6(3):955-66. Epub 2007 Jan 23.

PMID:
17243662
40.

Rating the raters: assessing the quality of Hamilton rating scale for depression clinical interviews in two industry-sponsored clinical drug trials.

Engelhardt N, Feiger AD, Cogger KO, Sikich D, DeBrota DJ, Lipsitz JD, Kobak KA, Evans KR, Potter WZ.

J Clin Psychopharmacol. 2006 Feb;26(1):71-4.

PMID:
16415710
41.

Biomarkers in psychotropic drug development: integration of data across multiple domains.

Bieck PR, Potter WZ.

Annu Rev Pharmacol Toxicol. 2005;45:227-46. Review.

PMID:
15822176
42.

Neurophysiologic correlates of side effects in normal subjects randomized to venlafaxine or placebo.

Hunter AM, Leuchter AF, Morgan ML, Cook IA, Abrams M, Siegman B, DeBrota DJ, Potter WZ.

Neuropsychopharmacology. 2005 Apr;30(4):792-9.

43.

Chronic lithium administration enhances noradrenergic responses to intravenous administration of the alpha2 antagonist idazoxan in healthy volunteers.

Ozerdem A, Schmidt ME, Manji HK, Risinger RC, Potter WZ.

J Clin Psychopharmacol. 2004 Apr;24(2):150-4.

PMID:
15206661
44.

Clinical assessment of norepinephrine transporter blockade through biochemical and pharmacological profiles.

Vincent S, Bieck PR, Garland EM, Loghin C, Bymaster FP, Black BK, Gonzales C, Potter WZ, Robertson D.

Circulation. 2004 Jun 29;109(25):3202-7. Epub 2004 Jun 7.

PMID:
15184278
45.

Serotonin transporter occupancy of five selective serotonin reuptake inhibitors at different doses: an [11C]DASB positron emission tomography study.

Meyer JH, Wilson AA, Sagrati S, Hussey D, Carella A, Potter WZ, Ginovart N, Spencer EP, Cheok A, Houle S.

Am J Psychiatry. 2004 May;161(5):826-35.

PMID:
15121647
46.

LY354740, an mGlu2/3 receptor agonist as a novel approach to treat anxiety/stress.

Schoepp DD, Wright RA, Levine LR, Gaydos B, Potter WZ.

Stress. 2003 Sep;6(3):189-97. Review.

PMID:
13129812
47.

Duloxetine increases serotonin and norepinephrine availability in healthy subjects: a double-blind, controlled study.

Chalon SA, Granier LA, Vandenhende FR, Bieck PR, Bymaster FP, Joliat MJ, Hirth C, Potter WZ.

Neuropsychopharmacology. 2003 Sep;28(9):1685-93. Epub 2003 May 28.

48.

Assessing and interpreting treatment effects in longitudinal clinical trials with missing data.

Mallinckrodt CH, Sanger TM, Dubé S, DeBrota DJ, Molenberghs G, Carroll RJ, Potter WZ, Tollefson GD.

Biol Psychiatry. 2003 Apr 15;53(8):754-60.

PMID:
12706959
49.

Dual monoamine modulation for improved treatment of major depressive disorder.

Tran PV, Bymaster FP, McNamara RK, Potter WZ.

J Clin Psychopharmacol. 2003 Feb;23(1):78-86. Review. Erratum in: J Clin Psychopharmacol. 2003 Aug;23(4):425.

PMID:
12544378
50.

Results from 2 proof-of-concept, placebo-controlled studies of atomoxetine in children with attention-deficit/hyperactivity disorder.

Spencer T, Heiligenstein JH, Biederman J, Faries DE, Kratochvil CJ, Conners CK, Potter WZ.

J Clin Psychiatry. 2002 Dec;63(12):1140-7.

PMID:
12523874

Supplemental Content

Loading ...
Support Center